secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001708599-25-000135
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics Q3 net loss $4.6M; FDA places SER-252 on clinical hold
--------------------------------------------------------------------------

- Net loss of $4.6M ($0.45 per share) vs net income of $1.4M in Q3 2024.
- FDA placed IND for SER-252 on clinical hold due to excipient question; not related to active drug.
- Secured up to $20M convertible note/warrant financing; first $5M drawn in September 2025.
- ATM program raised $2.8M net; 474,712 shares issued at avg $6.00 per share.
- Cash $8.6M as of Sept 30; R&D expenses rose to $3.6M from $2.4M year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000135/0001708599-25-000135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000135/ser-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer